The heart does not beat on its own—its rhythm is governed by a tiny cluster of cells in the right atrium known as the sinoatrial node. This node generates electrical impulses that force the organ to contract at a precisely controlled pace. When this node malfunctions, patients face life-threatening arrhythmias. Until now, metal pacemakers have remained the only reliable solution. But is it possible to recreate this complex mechanism using living cells?
A research team from the Shanghai Institute of Biochemistry and Cell Biology has taken a major step toward that goal. Using human pluripotent stem cells, the scientists grew a full three-dimensional sinoatrial node organoid in a Petri dish for the first time, rather than just pulsing tissue. Their findings, published in the journal Cell Stem Cell, detail the creation of what is known as a biological pacemaker.
The primary challenge was not simply making the cells contract. Instead, it was finding a way to make them respond to the nervous system. In a living body, heart rate is constantly adjusted by signals from the brain. To replicate this process, the Shanghai biologists combined the pacemaker organoid with a lab-grown ganglion plexus rich in neurons.
The experiment was a success: nerve fibers grew into the artificial node on their own and began regulating its beat frequency via molecular signals, perfectly mimicking the natural mechanism.
Why did scientists need such a precise assembly? Studying heart rhythm disorders in mice is ineffective because their hearts beat too fast, and obtaining samples of a living human sinoatrial node is practically impossible for obvious reasons. This new three-component "nerve-node-atrium" model allowed researchers to recreate genetic arrhythmia directly in the laboratory. By introducing a specific mutation, they recorded a slowing heart rate and then successfully tested potassium channel blockers that restored the pulse to normal.
Does this mean the era of titanium devices implanted under the skin is over? Not yet. Numerous safety hurdles, ranging from long-term cell survival to rejection prevention, must be cleared before such biological constructs can be implanted in human patients. Nevertheless, the technological foundation has been established. The platform already allows pharmaceutical companies to test new arrhythmia medications on authentic human tissue, bringing the future of personalized medicine significantly closer.
